Similar articles for PMID: 23392214

Year	Number of Results
1949	1
1972	1
1985	2
1992	1
1993	1
1996	1
1999	2
2002	2
2005	3
2006	2
2007	2
2008	2
2009	6
2010	5
2011	8
2012	14
2013	8
2014	7
2015	11
2016	11
2017	7
2018	5
2019	3
2020	5
2021	6
2022	5
2023	1
2024	0

1

GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases.

Zoicas F, Droste M, Mayr B, Buchfelder M, Schöfl C. Zoicas F, et al. Eur J Endocrinol. 2013 Apr 15;168(5):699-706. doi: 10.1530/EJE-12-0997. Print 2013 May. Eur J Endocrinol. 2013. PMID: 23392214

2

GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.

Beiroa D, Imbernon M, Gallego R, Senra A, Herranz D, Villarroya F, Serrano M, Fernø J, Salvador J, Escalada J, Dieguez C, Lopez M, Frühbeck G, Nogueiras R. Beiroa D, et al. Diabetes. 2014 Oct;63(10):3346-58. doi: 10.2337/db14-0302. Epub 2014 Jun 10. Diabetes. 2014. PMID: 24917578

3

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.

Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z. Wang B, et al. Diabetes Obes Metab. 2013 Aug;15(8):737-49. doi: 10.1111/dom.12085. Epub 2013 Mar 20. Diabetes Obes Metab. 2013. PMID: 23433305

4

Liraglutide for type 2 diabetes?

[No authors listed] [No authors listed] Drug Ther Bull. 2010 May;48(5):50-3. doi: 10.1136/dtb.2010.01.0006. Drug Ther Bull. 2010. PMID: 20447980 Review.

5

[Effects of glucagon-like peptide-1 on appetite and body weight: preclinical and clinical data].

Sesti G. Sesti G. G Ital Cardiol (Rome). 2011 Dec;12(12 Suppl 2):10-6. doi: 10.1714/985.10685. G Ital Cardiol (Rome). 2011. PMID: 22158422 Review. Italian.

6

A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice.

van Velsen EF, Lamers J, Blok V, van Leendert RJ, Kiewiet-Kemper RM. van Velsen EF, et al. Neth J Med. 2014 Dec;72(10):523-7. Neth J Med. 2014. PMID: 26219757 Free article.

7

Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.

Tzefos M, Harris K, Brackett A. Tzefos M, et al. Ann Pharmacother. 2012 Jan;46(1):68-78. doi: 10.1345/aph.1Q379. Ann Pharmacother. 2012. PMID: 22232377 Review.

8

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.

Vergès B, Bonnard C, Renard E. Vergès B, et al. Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25. Diabetes Metab. 2011. PMID: 21871831 Review.

9

Liraglutide as a potentially useful agent for regulating appetite in diabetic patients with hypothalamic hyperphagia and obesity.

Ando T, Haraguchi A, Matsunaga T, Natsuda S, Yamasaki H, Usa T, Kawakami A. Ando T, et al. Intern Med. 2014;53(16):1791-5. doi: 10.2169/internalmedicine.53.1646. Epub 2014 Aug 15. Intern Med. 2014. PMID: 25130112 Free article.

10

Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.

Thong KY, Ryder RE, Cull ML, Walton C; ABCD Nationwide Exenatide and Liraglutide Audit Contributors. Thong KY, et al. Diabet Med. 2012 May;29(5):690-2. doi: 10.1111/j.1464-5491.2011.03475.x. Diabet Med. 2012. PMID: 21988449 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

116 results

Results by year